Willow Grove, PA, Jan. 03, 2017 -- Azzur Group, LLC, a private equity firm with holdings in the life sciences consulting industry, is pleased to announce the acquisition of US-based training company, Learnaboutgmp.
Learnaboutgmp is an online training and education platform for biotechnology, pharmaceutical, and medical device companies. This platform has allowed some of the top international pharmaceutical companies to greatly increase their compliance knowledge and compliment their existing in-house training. The acquisition will allow Azzur Group to offer clients and competitors alike convenient and actionable training.
“We believe Learnaboutgmp is the resource that many companies have been looking for to add strength to their current team members and to allow members to grow in their career in the life science field,” said Thomas O’Donnell, Managing Partner of Azzur Group. "We are excited for the opportunities this new partnership will bring to our existing client base, and for the strength it will bring our incoming clients to bridge this talent gap.”
Visit Learnaboutgmp.com to find out more, and to sign up for a free 14 day trial and demo.
About Azzur Group, LLC- Azzur Group is a private equity firm comprised of a network of high-level life science companies, created to provide efficient and cost-effective solutions. As one of the fastest-growing, private companies in America, Azzur is firmly focused on providing seamless service to our customers. Our team of experienced industry professionals serves the pharmaceutical, biotechnology, and medical device industry by providing one-stop access to a wide-range of project management, process engineering, and compliance services within the life science industry.
About Learnaboutgmp- Learnaboutgmp is a cloud-based learning management system (LMS) designed specifically for life science and regulatory organizations. Our LMS contains the courses you need to help you achieve regulatory compliance. With new courses published every month and existing courses updated in line with regulatory changes, we are your true continuous learning platform.
“Learnaboutgmp’s content is developed by leading subject experts resulting in courses that are current, relevant and meaningful to learners. Every course was given a huge thumbs up by our internal Quality Systems leaders. Hands down, working with Learnaboutgmp has been one of the best engagements we have had in over 18 years of managing vendor course content and relationships. I highly recommend them to any Pharma organization interested in deploying top notch GMP related courseware.”
- VP, Global Quality Learning Top 5 Pharma Company
Graham O’Keeffe CEO [email protected] 4315 Independence Drive Schnecksville, PA, 18078 USA 315.636.4782


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Apple Turns 50: From Garage Startup to AI Crossroads
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



